Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial

IMPORTANCE: With few approved multiple sclerosis therapies in the pediatric population, there is a need for further approved treatment options. Limited data exist for dimethyl fumarate (DMF) treatment in pediatric-onset multiple sclerosis (POMS). OBJECTIVE: To compare the efficacy, safety, and toler...

Descripción completa

Detalles Bibliográficos
Autores principales: Vermersch, Patrick, Scaramozza, Matthew, Levin, Seth, Alroughani, Raed, Deiva, Kumaran, Pozzilli, Carlo, Lyons, Jennifer, Mokliatchouk, Oksana, Pultz, Joe, N’Dure, Fatou, Liu, Shifang, Badwan, Runda, Branco, Filipe, Hood-Humphrey, Valencia, Franchimont, Nathalie, Hanna, Jerome, Maghzi, Amir-Hadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520348/
https://www.ncbi.nlm.nih.gov/pubmed/36169959
http://dx.doi.org/10.1001/jamanetworkopen.2022.30439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520348/
https://www.ncbi.nlm.nih.gov/pubmed/36169959
http://dx.doi.org/10.1001/jamanetworkopen.2022.30439

Ejemplares similares